News

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — —…

2 years ago

Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

Dr. Turgeon is an esteemed Clinical Professor at University of Michigan Health and clinical translational researcher with specific research interest…

2 years ago

Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases

The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a…

2 years ago

Assertio Prices $60 Million Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024

LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty…

2 years ago

Bright Minds Announces Overnight Marketed Offering of Units

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE…

2 years ago

Atrion Corporation Increases Quarterly Cash Dividend by 10%

ALLEN, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Atrion Corporation (Nasdaq ATRI) today announced an increase in its quarterly cash…

2 years ago

Elevar Therapeutics Names Wade Smith Chief Financial Officer

Two-decade industry veteran joined Elevar as VP of finance in January Elevar Therapeutics Names Wade Smith Chief Financial Officer Wade…

2 years ago

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer…

2 years ago

ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS

Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses…

2 years ago